Trial Profile

A Phase 1, Open-label Study to Evaluate SGN-35C in Adults With Advanced Malignancies.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGN 35C (Primary)
Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
Focus Adverse reactions; First in man
Sponsors Seagen

Most Recent Events

21 Feb 2025 Planned End Date changed from 31 Aug 2028 to 4 Apr 2029.
21 Feb 2025 Planned primary completion date changed from 28 Feb 2028 to 4 Apr 2028.
10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com